drugset / Trial / NCT04700046
Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2
RandomizedParallel-groupTriple-blindTreatment
Summary
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Mexiletine During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 \[The MIND Study\]
Timeline
- Start
- 2021-09-03
- Primary completion
- 2024-07-01
- Completion
- 2024-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mexiletine | Small molecule | 167 mg | Oral |